Iridian Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Iridian Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-24,392	Closed	-$458K	–	90
2015 Q3	$458K	Hold	24,392	–	–	﹤0.01%	64
2015 Q2	$363K	Buy	24,392 +13,542	+125%	+$206K	﹤0.01%	74
2015 Q1	$164K	Hold	10,850	–	–	﹤0.01%	66
2014 Q4	$145K	Sell	10,850 -3,430	-24%	-$44.3K	﹤0.01%	69
2014 Q3	$180K	Buy	+14,280	New	+$139K	﹤0.01%	96

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Iridian Asset Management's CNCE Position: Q4 2015 in Review

Iridian Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2015, closing a stake of 24,392 shares — an estimated $458K sold.

Iridian Asset Management first reported a position in CNCE in Q3 2014 and held it in 5 quarters. The position peaked at $458K in Q3 2015. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2015.

Iridian Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
Iridian Asset Management sold 24,392 Concert Pharmaceuticals, Inc. shares in Q4 2015, an estimated $458K.
Iridian Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 5 quarters.
Iridian Asset Management's Concert Pharmaceuticals, Inc. position peaked at $458K in Q3 2015.
93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2015.

Based on Iridian Asset Management's 13F filing for Q4 2015, filed 5 Feb 2016.